

ASX release

2 May 2023

Presentation to the Macquarie Australia Conference and FY23 outlook update

Medibank Chief Executive Officer David Koczkar will be delivering the attached presentation at the Macquarie Australia Conference which includes an update to Medibank's FY23 outlook.

This document has been authorised for release by the Board.

For further information please contact:

For media

Emily Ritchie Senior Executive, External Affairs M: +61 429 642 418 Email: Emily.Ritchie@medibank.com.au

For investors/analysts

Colette Campbell Senior Executive, Investor Relations T: +61 475 975 770 Email: investor.relations@medibank.com.au



medibank

Macquarie Australia Conference

David Koczkar – Chief Executive Officer

2 – 3 May 2023

Important notice

General & Summary Information

The information contained in this presentation is general information about Medibank Private Limited ("MPL") and / or its related bodies corporate (together, "MPL Group") and their activities current as at the date of the presentation. The information is given in summary form and does not purport to be complete. It is intended to be read in conjunction with the verbal presentation delivered on the date of the presentation and MPL's other periodic and continuous disclosure announcements lodged with the ASX or released on MPL's website which are available at www.medibank.com.au.

Not advice

The information contained in this presentation is not investment, legal, tax or other advice and has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. You should make your own assessment and seek independent professional advice in connection with any investment decision. Past performance information in this presentation is given for illustrative purposes only. It is not, and should not be relied upon as, an indication of future performance.

To the extent permitted by law, no responsibility for any loss arising in any way from anyone acting or refraining from acting as a result of this information is accepted by MPL or any of its related bodies corporate. No representation or warranty, express or implied, is made by any person, including MPL, and its related bodies corporate, their respective directors, officers, employees, professional advisors and agents ("Related Parties") as to the fairness, accuracy, completeness, reliability or correctness of the information, opinions and conclusions contained in this presentation, including any forward-looking statements.

Forward-looking statements

This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of the MPL Group and certain plans and objectives of the management of MPL. Forward-looking statements can be identified by the use of forward-looking terminology, including without limitation the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "aspiration", "guidance", "forecasts", "continue", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. Statements about market and industry trends are also forward-looking statements.

These forward-looking statements are provided as a general guide only and are not guarantees or predictions of future performance. They are based on information, expectations and assumptions known to MPL as at the date of this presentation regarding MPL's present and future business strategies and the future political, regulatory and economic environment in which MPL will operate.

MPL believes the expectations reflected in these forward-looking statements are reasonable as at the date of this presentation, but acknowledge they involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of MPL, which may cause the actual results or performance of MPL to be materially different from the results or performance expressed or implied by such forward-looking statements. These factors include general economic conditions in Australia, exchange rates, the market environment in which MPL operates and inherent regulatory risks in MPL's business, and those set out on slides 5, 6 and 10.

You are therefore cautioned not to place undue reliance on any forward-looking statements regarding our belief, intent or expectations with respect to the MPL Group's businesses, market conditions and/or results of operations.

No representation or warranty is made by any legal or natural person in relation to the accuracy, likelihood of achievement or reasonableness of any of these forward-looking statements, forecasts, prospects or results (express or implied). MPL and its Related Parties assume no obligation to update any forward-looking statement and to the full extent permitted by law, MPL and its Related Parties disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including but not limited to any assumptions or expectations set out in the presentation).

Financial data and rounding

Unless stated otherwise, all figures in the presentation are in Australian dollars. Some figures, amounts, percentages, estimates, calculations of value and fractions are subject to rounding. Accordingly, the actual calculations of these figures may differ from figures set out in this presentation. Further, some balances subject to rounding may not add consistently throughout this presentation.

No offer or sale

The distribution of this presentation, including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions. Nothing in this presentation constitutes an offer or invitation to issue or sell securities, or a recommendation to subscribe for or acquire securities, by or on behalf of MPL, its related bodies corporate or any other person in any jurisdiction including where it is unlawful to do so. This presentation is not and does not constitute an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released, directly or indirectly, in the United States.

Abbreviations and acronyms used throughout the presentation may be found in the glossary.

Acknowledgment of Country

Medibank acknowledges Aboriginal and Torres Strait Islander peoples as the First Peoples of this nation.

We proudly recognise Elders past, present and emerging as the Traditional Owners and Custodians of the lands on which we work and live.

We're committed to supporting self-determination and envision a future where all Australians embrace Aboriginal and Torres Strait Islander histories, cultures and rights as a central part of our national identity.

Key points

medibank

Stable resident policyholder growth

Strong growth in non-resident PHI with growing relevance to Medibank

Megatrends in health will continue to drive patient-centric outcomes

Our vision is to create the best health and wellbeing for Australia

Cybercrime update

- Industry growth remains strong with a continuation of factors supporting participation
- Service NPS recovery in both brands
- FYTD policyholder growth of 0.4k policyholders or 0.02% (as at 31 Mar 23)
- Expect a strong 4Q, with positive momentum leading into FY24
- Expect to announce a further customer give back before 30 Jun 23
- Strong rebound in student, worker and visitor visas
- Strong FYTD policy unit growth of 62k, to 258.5k policy units (as at 31 Mar 23)
- Differentiated offerings, investment and future partnerships will support further growth
- Greater adoption and access to new care settings provides Australians with more choice, value and control of their health
- Medibank is evolving its relationship with partners
- Our strategy continues to meet the changing needs of customers while generating value for shareholders and bringing about much needed change in the health system
- We continue to expand our reach in health in both the private and public system, building strong relationships with multiple health providers with new relationships including:
 - o JV with Aurora Healthcare to deliver an innovative integrated mental health care model
 - o GP-led initiative referring Myhealth patients to Medibank's Type 2 Diabetes Program
 - o North Coast Health Connect, offering Coffs Harbour residents virtual healthcare
- Medibank has been provided with Deloitte's findings from their external incident review
- Deloitte made recommendations to enhance Medibank's IT processes and systems, a number of which have already been implemented
- At this stage we do not expect a material increase to recurring IT costs resulting from the cybercrime

Stable resident policyholder growth

We will maintain our disciplined approach to growth in a highly competitive and growing market

Industry growth remains resilient

Industry growth continues

- Expect FY23 industry policyholder growth of c. 2% (FY22: 2.7%)
 - Estimate Adult Dependent Reform (ADR) will reduce FY23 industry policyholder growth by c. 0.4% (not in prior period) – ADR will not impact hospital lives insured
 Impacted by Medibank performance in Q2
- Subdued switching continues
- Strong growth in hospital lives continues with some recent softness in extras-only

ADR expected to be positive for long-term industry growth and quality

- Increased retention for customers turning 25 who remain on their family's policy
- Expect impact to be fully realised in 5 years
- Increased continuity of cover when customers turn 31

Factors supporting continued participation

- Environmental factors: Population growth, strong wage growth and low unemployment
- Industry factors: Increasing consumer spending on health and public system still under strain
- Affordability: Low premium increases with continued COVID give-backs to help address cost of living challenges

ADR will have a short-term negative impact on policyholder growth but minimal impact on hospital lives¹



Medibank recovery tracking as expected

Policyholder growth stabilising

- FYTD policyholder growth of 0.4k policyholders or 0.02% (as at 31 Mar 23)
- Similar ADR impact to industry however retained an additional c. 18k adult dependents
- FY23 downgrading not expected to exceed 1H23 (70 bps)
- Expect a strong Q4 and on track to achieve FY23 policyholder growth outlook

Well positioned to grow beyond FY23

- Service NPS recovery in both brands, exceeding benchmark levels
- Lapse intent is at pre-cybercrime levels
- Expect to announce further customer give backs before 30 Jun 23
- Well-positioned to address cost of living concerns and health needs through continued investment in our dual brand proposition

Policyholder volumes ('000) have started to stabilise



medihank

Strong growth in non-resident PHI

Key future growth pillar

medibank

Non-resident market is recovering and growing

Strong growth in student, worker and visitor market segments

- Working visas exceed pre-COVID levels
- Strong rebound in student and visitor visas

Factors supporting continued growth

- Australia's continued immigration strategy
- Recovery in international student arrivals, particularly from China and India
- Visitor arrivals expected to surpass pre-COVID levels by 2025

Primary visa holder data¹ shows a recovery in international students and workers coming to Australia



1 Workers segment includes key contestable visa categories eligible for Medibank's Overseas Workers Health Covers. Bridging visa holders in Australia excluded from all segments. Source Data.gov.au, accessed May 2023

We will continue to invest for growth

Policy unit growth accelerating since June 2022

- FYTD policy unit growth of 62.0k to 258.5k (at 31 Mar 23)
- 。 3-month growth of 28.6k policies vs. 1H23 growth of 33.4k
- $_{\circ}~$ On track for FY23 to have the highest joins in 5 years
- Strong growth in international student policies
 - $_{\circ}~$ Underpinned by university account wins
 - $_{\circ}~$ Supports future growth as customers transition to other visa subclasses
- Uplift in workers and visitors segments with strong digital joins
- We now expect FY23 non-resident gross profit to approximately double from FY22, which will result in a similar benefit to PHI gross margin as the first half

Well positioned to grow beyond FY23

- Continue to differentiate our products and services and improve product value through integrated health offerings and additional investment
- Opportunity to win share in workers segment where under indexed



Short stay model of care will benefit the entire health system


Megatrends in health will continue to drive patient-centric outcomes

	nsumerisation OQ The shift to health		se of new the set of	Outcome-based care	
	Short stay – joint replacement example		Short stay model will bri	ing positive impacts	
Customer needs	Choice of care		Standard care pathway 🛛 → Short stay model		
	 Transparency, reduction or elimination of out-of-pocket costs Reduction in hospital stays where clinically appropriate 	Customer impacts	Patient satisfaction ² NPS 55.2	NPS 71	
How we respond	 Partnership with specialists and hospitals Integrated into a wide range of hospital covers No gap joint replacement program is locally available to 65% of Medibank customers¹ c. 4% of Medibank's joint replacement procedures are now through 		Out-of-pocket savings	c. \$1.4k per episode of care	
		Costs per episode of care	Hospital stay costs	Lower due to average length of stay reducing by 50% ²	
	short stay model (FY21: 2.2%)	-	Medical specialists	Higher payment to specialists to eliminate customer out-of-pocket costs	
	 Value and choice where clinically appropriate Better customer experience through shorter hospital stays and 		Rehab costs In-hospital (c. \$9,000)	At-home rehab (c. \$2,800)	
	no gap offering Medibank		Prosthesis costs c. \$7.5k (22%-25% of overall cost)	c. \$7.5k (28%-31% of overall cost)	
	 Supports retention through better customer experiences Reduces benefit outlays Participation in this market segment through hospital investments 		Overall costs c. \$30k-\$33k	c. \$24k-\$27k	
	 Failed participation in this market segment through hospital investments Health system Frees up resources for more acute needs More affordable care supports overall participation 	Long-term opportunities	 Gaining efficiencies with less need to invest in in-patient rehab facilities Capex can be directed to develop fit-for-purpose healthcare setting Opportunities to bring prothesis costs down through reform 		

2 KPMG. Medibank facilitates a sustainable healthcare system. July 2022

Medibank is evolving its relationship with partners


Megatrends in health will continue to drive patient-centric outcomes



Our vision is to create the best health and wellbeing for Australia

medibank

We are uniquely positioned to support customers and grow with the collective strength of our products and offerings



FY23 outlook update

As presented at 1H23 Results			Updates	
\$ \$	Customer relief	We continue to assess claims activity and any permanent net claims savings due to COVID-19 will be given back to customers through additional support in the future	Expect to announce a further customer give back before 30 June 2023	
<u>®</u>	Resident policyholder growth	We expect resident policyholder growth of approximately 0.5%-0.75% assuming recent trends continue and a modest decline in industry growth rate in FY23 relative to FY22	 No change FYTD policyholder growth of 0.4k policyholders or 0.02% (as at 31 Mar 23) 	
30	Claims	Underlying claims per policy unit growth of 2.3% for FY23 among resident policyholders	 No change Whilst there has been a modest uplift in cash claims paid since 31 Dec 22, they remain significantly below our underlying claims expectations 	
<u>®</u> 7	Non-resident growth	Non-resident gross profit in 2H23 expected to be higher than 1H23	 FY23 non-resident gross profit expected to approximately double from FY22, which will result in a similar benefit to PHI gross margin as the first half FYTD policy unit growth of 62.0k to 258.5k (at 31 Mar 23) 	
ξ.	PHI management expenses	FY23 management expenses expected to be c. \$560mFY23 underlying MER not expected to be above FY22Target \$30m productivity savings in FY23-FY25, including \$10m in FY23	No change	
	Cybercrime costs	 Non-recurring FY23 cybercrime costs expected to be \$40m-\$45m Includes non-recurring investment in IT security Excludes further potential customer and other remediation, regulatory or litigation related costs 	 Non-recurring FY23 cybercrime costs expected to be at the top end of the \$40m-\$45m range At this stage we do not expect a material increase to recurring IT costs resulting from the cybercrime 	
19	Growth	Targeted organic and inorganic growth for Medibank Health and Health Insurance remain areas of focus, supported by a strong capital position	No change	



medibank

Appendix

Our health investments

Target markets	Investments	Ownership interest (%)	Description	Benefits to Medibank	
	Myhealth Medical Holdings Pty Ltd	49%	 Medibank acquired a non-controlling interest in Myhealth Medical Group for c. \$63m in 2021 	Support preventative health and GP- led proactive care management	
Primary care	Medinet Australia Pty Ltd	3.85%	 Medibank invested \$10m in health tech company Medinet in 2022 and has 28.5% of the voting rights Medinet provides platform helping GPs to connect with their patients 	Continue to grow our virtual care capabilities	
Homecare	Calvary Medibank JV Pty Ltd	50%	 Since 2020, the JV has been providing My Home Hospital program for Wellbeing SA and COVID Care At Home in a number of states 	Continue to grow our homecare capabilities	
	East Sydney Day Hospital Pty Ltd	49%	 Medibank's initial investment of \$8.8m in 2020 to fund capital investment and operational costs required for the hospital to scale its short stay model of care 		
Hospitals, including short stay	Adeney Private Hospital Pty Ltd 49% • The JV between a group of doctors and Medibank will establish a new short stay surgical facility in Kew Melbourne Medibank's contribution to date is \$6.2m, with a further commitment of \$2.8m, totalling \$9m • Expected to open in mid 2024		Expand our hospital investments		
	SydOrtho Holdings Pty Ltd (holding company) supporting MQ Health to establish a surgical facility	50%	 Medibank invested \$1.5m (with a total commitment of \$14.8m) in 2022 to establish a JV with orthopaedic surgeons to support the establishment of an orthopaedic surgical centre at Macquarie University Hospital MQ Health is contributing the floor space, with the centre to operate as an integrated part of the hospital 		
	Integrated Mental Health Pty Ltd (iMH)	50%	 A JV with Aurora Healthcare to deliver an innovative integrated mental health model that extends hospital care to incorporate additional support services in home and community settings The JV will initially invest \$31m into three hospitals delivering a combined 153 new mental health beds and comprehensive out-of-hospital support 		

Glossary

Term	Definition	Term	Definition	
1H	ix months ended/ending 31 December of the relevant nancial year Policyholder		The primary person who is insured under a private health insurance policy (other than	
2H	Six months ended/ending 30 June of the relevant financial year	Toticynolder	in relation to overseas students or visitors), who is not a dependen child, and who is responsible for paying the premium	
Adult Dependent Reform	Reform that allows adult dependents to remain on their parents private health insurance policies until they turn 31	PSEUs or	Policy Single Equivalent Units are used by Medibank as a standard measure of income units. They take into account the number of adults on a policy, and whether they have Hospital Cover or Extras	
APRA	Australian Prudential Regulation Authority	policy units	Cover or both. For example, a household with two parents and three children, all of which had both Hospital and Extras Cover, would represent four policy units (2 adults x 2 types of Cover = 4). This measure includes residents and non-resident policies and only adult insureds are typically counted in the calculation of PSEUs	
bps	Basis points (1.0% = 100 bps)			
Downgrading	The difference between the average premium rate rise and revenue growth per policy unit			
FY	Financial year ended/ending 30 June	Resident PHI	Hospital and/or extras cover for a compliant health insurance	
Health Insurance	Includes both resident and non-resident		product Service net promoter score. A measure of the likelihood of an existing customer to recommend the brand immediately following a service interaction	
Hospital Lives	The number of people in Australia who are covered by resident private health insurance hospital product	Service NPS		
Live Better	A Medibank program to inspire people to lead a healthier and happier lifestyle, with tools and rewards (for eligible members) to motivate people			
Members Choice Advantage	An enhanced network of ancillary providers where customers can enjoy better value on eligible extras services. Includes dental and optical providers, physiotherapy, chiropractic, podiatry, acupuncture and remedial massage			
MER	Management expense ratio			
Non-resident PHI	Overseas visitor, working visa and student health covers			
PHI	Private Health Insurance		13	